Guided Therapeutics (GTHP) Convertible Debt (2014 - 2026)

Guided Therapeutics has disclosed Convertible Debt across 13 years of filings, most recently posting $20000.0 for Q2 2026.

• In Q2 2026, Convertible Debt changed N/A year-over-year to $20000.0; the TTM figure through Jun 2026 stood at $20000.0 (changed N/A YoY), while the FY2024 annual figure was $14000.0, changed N/A from the prior year.
• Convertible Debt came in at $20000.0 for Q2 2026 at Guided Therapeutics, down from $75000.0 in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $1.1 million in Q1 2024 to a low of $14000.0 in Q4 2024.
• Average Convertible Debt over 5 years is $692916.7, with a median of $933000.0 recorded in 2022.
• Year-over-year, Convertible Debt tumbled 96.9% in 2025 and soared 114.29% in 2026.
• Over 5 years, Convertible Debt stood at $1.0 million in 2022, then declined by 6.12% to $982000.0 in 2023, then sank by 98.57% to $14000.0 in 2024, then jumped by 150.0% to $35000.0 in 2025, then slumped by 42.86% to $20000.0 in 2026.
• Per Business Quant data, the three most recent Convertible Debt figures were $20000.0 in Q2 2026, $75000.0 in Q1 2026, and $35000.0 in Q1 2025.